XGX Pharma ApS: Financial statements 2018
CVR: 32289290
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 1,574,797 and a net result of DKK 26,878 compared with DKK -189,057 the year before. That is an increase of 1,408% compared with the year before. Equity in the 2018 report amounted to DKK 59,347. The solvency ratio was 1.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,574,797
- Profit/Loss
- DKK 26,878
- Equity
- DKK 59,347
- Total Assets
- DKK 3,486,915
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 1.6 mio. | 27 t. | 59 t. | 1 |
| 2017 | - | 104 t. | -189 t. | 32 t. | - |
| 2016 | - | 307 t. | 272 t. | 92 t. | - |
| 2015 | - | -33 t. | -35 t. | -180 t. | - |
| 2014 | - | - | -14 t. | -145 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of November 1, 2018, Mohammad Sohail Asghar has joined the board of directors of XGX Pharma ApS.
As of November 1, 2018, Per Ludvigsen has joined the board of directors of XGX Pharma ApS.
As of November 1, 2018, Jens-Nikolaj Schøier has joined the board of directors of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2017. Gross profit came to DKK 104,432, and the net result was DKK -189,057.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.